Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Gonadorelin is a synthetic decapeptide identical in sequence to native gonadotropin-releasing hormone (GnRH): pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. It is the parent compound of all GnRH-receptor agonists used in medicine — leuprolide, goserelin, triptorelin, and others — but is itself unmodified and so retains the very short half-life of native GnRH.
Native GnRH is released in pulses from hypothalamic neurons every 60 to 120 minutes during the reproductive years. The pulsatile pattern is essential: continuous GnRH exposure paradoxically suppresses pituitary gonadotropin release, which is the basis of the long-acting GnRH agonists used in prostate cancer and endometriosis. Gonadorelin used clinically tries to reproduce the natural pulsatile pattern rather than block it.
History
Andrew Schally's lab at Tulane isolated and sequenced GnRH from porcine hypothalami in 1971, work that contributed to his 1977 Nobel Prize. The synthetic form, gonadorelin, was developed almost immediately and entered clinical use in Europe by the mid-1970s. The FDA approved gonadorelin under the brand name Factrel in 1982 for diagnostic use (evaluating pituitary gonadotropin reserve) and for inducing ovulation in women with hypothalamic amenorrhea via pulsatile pump administration. A second brand, Lutrepulse, was approved for the pulsatile pump indication.
Both Factrel and Lutrepulse have since been discontinued in the United States, primarily for commercial rather than safety reasons. In the United Kingdom and parts of Europe, branded HRF (gonadorelin acetate) remains available for the pulsatile pump indication. In the United States, gonadorelin is currently most often prepared by 503A compounding pharmacies, where it is used as an adjunct to testosterone replacement therapy in men — to maintain testicular function during exogenous testosterone administration — and occasionally in fertility protocols.
Regulatory status
FDA approved 1982 (as Factrel) for diagnostic and therapeutic use; the branded product is no longer marketed in the United States. Compounded gonadorelin remains available through 503A pharmacies, and the substance is listed on the FDA 503A bulk substances list as a Category 1 (eligible for compounding) substance. Approved internationally under multiple brand names including HRF, Lutrelef, and Relefact.
The diagnostic indication — measuring pituitary LH and FSH response after a single intravenous dose — has been largely superseded by basal hormone measurement and other testing modalities. The therapeutic pulsatile pump indication for hypothalamic amenorrhea is still considered the most physiologic approach but is rarely used in current practice because of the complexity of pump management.
Mechanism
Gonadorelin binds the GnRH receptor (a Gq-coupled GPCR) on pituitary gonadotrope cells, triggering release of stored luteinizing hormone and follicle-stimulating hormone. The character of the response depends entirely on the pattern of exposure. Pulsatile delivery (one short exposure every 60 to 120 minutes) maintains receptor sensitivity and produces sustained gonadotropin release, which downstream stimulates gonadal steroidogenesis and gametogenesis. Continuous or rapidly repeated exposure desensitizes the receptor and ultimately suppresses gonadotropins — the mechanism used by the long-acting GnRH agonists like leuprolide.
The TRT-adjunct use of gonadorelin trades on this: small subcutaneous doses two or more times per week are intended to mimic the natural pulsatile signal closely enough to maintain endogenous LH release and testicular function during exogenous testosterone administration. The evidence base for this specific use is weaker than for the pulsatile pump indication and consists largely of case series and clinical practice rather than controlled trials.
Half-life and dosing intervals
Gonadorelin has a very short half-life — published distribution half-life is 2 to 10 minutes and terminal half-life is 10 to 40 minutes. This is the central feature of the molecule: its rapid clearance is what allows pulsatile administration to mimic the natural signal.
Approved pulsatile pump dosing for hypothalamic amenorrhea is typically 5 to 20 mcg per pulse subcutaneously every 90 minutes, with the pump worn continuously over multiple weeks. For diagnostic use, a single 100 mcg intravenous dose was the labeled protocol. In TRT-adjunct compounded use, doses of 50 to 200 mcg subcutaneously two to three times per week are common, with substantial variation between protocols.
Reconstitution example
Compounded gonadorelin is typically supplied lyophilized in vials of 3 mg or 10 mg. A 3 mg vial reconstituted with 3 mL of bacteriostatic water yields 1 mg/mL (1000 mcg/mL). On a 1 mL U-100 insulin syringe, 10 units (0.1 mL) delivers 100 mcg, and 5 units (0.05 mL) delivers 50 mcg. Vial's calculator handles the conversion when vial mass and water volume are entered.
What to know
- Approved drug, withdrawn brands. Factrel was a real FDA-approved product. Compounded gonadorelin is on the 503A list and is the form most commonly used today in the United States.
- Pattern matters more than dose. The biology of GnRH is built around pulsatility. Continuous high-dose exposure produces the opposite of the intended effect.
- TRT-adjunct use is off-label. The strongest evidence is for the pulsatile pump indication in hypothalamic amenorrhea. Subcutaneous twice-weekly use to maintain testicular function during testosterone replacement is widely practiced but not approval-supported.
- Common reported side effects: injection-site reactions, headache, occasional flushing or nausea. Anaphylactoid reactions have been reported rarely with the diagnostic intravenous dose.
- Storage. Lyophilized: refrigerate, protect from light. Reconstituted: refrigerate; gonadorelin is hygroscopic and degrades in solution. Stability data supports 1 to 2 weeks under refrigeration after reconstitution.
- Not the same as hCG. Gonadorelin acts at the pituitary to drive endogenous LH; hCG acts directly at the gonad as an LH mimic. The two are sometimes substituted for each other in TRT-adjunct practice but have different mechanisms.
Sources
- 1.Schally AV et al. (1971). Isolation and properties of the FSH and LH-releasing hormone. Biochemical and Biophysical Research Communications.
- 2.Crowley WF Jr et al. (1985). The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women. Recent Progress in Hormone Research.
- 3.Christin-Maitre S, Young J (2019). Pulsatile GnRH treatment for women with hypothalamic amenorrhea. Annales d'Endocrinologie.
- 4.Patel AH et al. (2024). Kisspeptin in functional hypothalamic amenorrhea: pathophysiology and therapeutic potential. Annals of the New York Academy of Sciences.